ModelEdge

Scinai Immunotherapeutics Ltd

Filing Type	20-F
Filing Date	3/27/2022
Updated	3/28/22, 12:50 AM

Filing

Earnings Release

Exhibits

20-FAnnual and Transition Report of Foreign Private Issuers

EX-4.4EMPLOYMENT AGREEMENT DATED JANUARY 20, 2021, BETWEEN BIONDVAX PHARMACEUTICALS LTD. AND MR. AMIR REICHMAN

EX-4.16LICENSE AGREEMENT, DATED DECEMBER 11, 2021, BETWEEN BIONDVAX PHARMACEUTICALS LTD. AND MAX-PLANCK-INNOVATION GMBH

EX-4.17ACCOMPANYING RESEARCH COLLABORATION AGREEMENT, DATED DECEMBER 11, 2021

EX-4.18RESEARCH COLLABORATION AGREEMENT, DATED MARCH 23, 2022, BETWEEN BIONDVAX PHARMACEUTICALS LTD., MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V AND GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVERSITATSMEDIZIN GOTTINGEN

EX-4.19FORM OF LICENSE AGREEMENT BETWEEN BIONDVAX PHARMACEUTICALS LTD., MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V AND GEORG-AUGUST-UNIVERSITAT GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVERSITATSMEDIZIN GOTTINGEN

EX-10CONSENT OF KOST FORER GABBAY & KASIERER, CERTIFIED PUBLIC ACCOUNTANT (ISR.), A MEMBER OF ERNST & YOUNG GLOBAL, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE REGISTRANT.

EX-12.1CERTIFICATION

EX-12.2CERTIFICATION

EX-13.1CERTIFICATION

EX-13.2CERTIFICATION